OTA 2013 Posters

Scientific Poster #33 Geriatric OTA 2013

Periprosthetic Femur Fractures: 1-Year Mortality Rates for Open Reduction and Internal Fixation and Revision Arthroplasty

Natalie Casemyr, MD1; Collin May, MD1; Mark Vrahas, MD1; Michael J. Weaver, MD2;
Edward K. Rodriguez, MD3; Mitchell Harris, MD2;
1Massachusetts General Hospital, Boston, Massachusetts, USA;
2Brigham and Women’s Hospital, Boston, Massachusetts, USA;
3Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA

Background/Purpose: Periprosthetic femur fractures (PPFFx) following total hip arthroplasty are complex injuries that are increasing in incidence. Patients with these injuries have high mortality rates, with some reports showing mortality rates approaching those of hip fracture patients. There are little data available, however, describing comparative mortality outcomes for these patients according to method of surgical treatment. The purpose of our study was to compare the survivorship for patients with Vancouver B PPFFx treated with open reduction and internal fixation (ORIF) versus revision arthroplasty, with subgroup analysis of Vancouver B1 and B2 fractures.

Methods: We performed an IRB-approved retrospective review of all patients who underwent surgical treatment for Vancouver B PPFFx at our institutions between 2003 and 2011. Patients were categorized into 2 treatment groups: ORIF or revision arthroplasty. Subgroup analysis of patients treated for Vancouver B1 and B2 fractures was performed. The primary outcome measure was survivorship as identified by the Social Security Death Index and analyzed using the Kaplan-Meier method. The secondary outcome measure was the incidence of major complications.

Results: 122 of 158 identified patients with Vancouver B PPFFx met our inclusion criteria for further analysis. The mean age was 75.7 ± 13.2, with 70 (57%) women. There were no significant cohort differences by age, sex, or Charlson comorbidity index between patients who underwent surgical treatment with ORIF versus revision arthroplasty. The mortality rate at 1 year for patients treated for Vancouver B PPFFx was 13.1%. American Society of Anesthesiologists (ASA) class was highly predictive of mortality (P = 0.001). Survivorship, as measured by the Kaplan-Meier method, was significantly decreased for patients treated with ORIF as compared to those treated with revision arthroplasty (P = 0.04). In patients ≥79 years old, poor survivorship outcomes persisted in patients treated with ORIF while treatment with revision arthroplasty exerted a protective effect on survivorship. The mortality rate at 1 year for patients treated for Vancouver B2 PPFFx was 15.3%. Survivorship for patients with Vancouver B2 fractures treated with ORIF was significantly decreased as compared to those treated with revision arthroplasty (P = 0.006). The overall complication rate was 41.8%, with 25.4% of patients experiencing major complications. The return to operating room rate was 17.2%. The Vancouver B2 revision arthroplasty cohort had a significantly greater number of overall complications (48.8%) and major complications (34.9%) than the Vancouver B2 ORIF cohort (20.6% and 10.3%, P = 0.04 and P = 0.005, respectively).

Conclusion: Patients with Vancouver B PPFFx treated with ORIF have significantly decreased survival compared to revision arthroplasty counterparts. In patients ≥79 years old, treatment with revision arthroplasty potentiates survival benefits. Patients with Vancouver B2 PPFFx treated with ORIF have highly significantly decreased survival compared to revision arthroplasty counterparts. Despite clear survival benefits, consideration for revision arthroplasty should be balanced with the significantly increased risk of major complications which often result in reoperation.

• The FDA has not cleared this drug and/or medical device for the use described in this presentation   (i.e., the drug or medical device is being discussed for an “off label” use).  ◆FDA information not available at time of printing. Δ OTA Grant.